---
schema_version: "secwatch.filing_event.v1"
accession: "0001815776-25-000030"
form_type: "8-K"
ticker: "LENZ"
cik: "0001815776"
company_name: "LENZ Therapeutics, Inc."
filed_at: "2025-05-07T23:59:59+00:00"
generated_at: "2026-05-22T08:44:52.059387+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# LENZ Therapeutics Q1 net loss $14.6M; LNZ100 PDUFA on track for Aug 8, 2025

## Summary
- Net loss $14.6M ($0.53 per share) vs $16.6M ($3.53) YoY; R&D down to $5.8M, SG&A up to $11.1M.
- Cash $194.1M at Mar 31, 2025; anticipated balance >$185M at PDUFA; runway to post-launch positive cash flow.
- NDA for LNZ100 (aceclidine eye drop for presbyopia) on track; FDA PDUFA target date Aug 8, 2025.
- US Customs rulings confirm LNZ100 US origin and duty free, eliminating tariff exposure.
- Pre-commercial hiring of 88 sales reps targeted by Jul 1, 2025; raised $16.3M net from April ATM block trade.

## SEC filing metadata
- accession: 0001815776-25-000030
- form_type: 8-K
- ticker: LENZ
- cik: 0001815776
- company_name: LENZ Therapeutics, Inc.
- filed_at: 2025-05-07T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1815776/000181577625000030/0001815776-25-000030-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1815776/000181577625000030/lenz-20250507.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001815776-25-000030
- JSON: https://secwatch.observer/filing/0001815776-25-000030.json
- Plain text: https://secwatch.observer/filing/0001815776-25-000030.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.